How to Get Advertising Content Reviewed and Approved in China: 2026 Step-by-Step Guide

Date:

Share post:

How to Get Advertising Content Reviewed and Approved in China: 2026 Step-by-Step Guide

Obtaining advertising content approval in China requires navigating a complex regulatory framework that involves at least 5 separate government bodies and a mandatory pre-review process for 12 specific product categories. As of 2026, China’s State Administration for Market Regulation (SAMR, 国家市场监督管理总局, guójiā shìchǎng jiāndū guǎnlǐ zǒngjú) oversees advertising compliance through 34 provincial and municipal bureaus, with industry-specific rules enforced by the National Medical Products Administration (NMPA, 国家药品监督管理局, guójiā yàopǐn jiāndū guǎnlǐ jú) and the Ministry of Industry and Information Technology (MIIT, 工业和信息化部, gōngyè hé xìnxīhuà bù). This guide provides a step-by-step roadmap for foreign executives to legally review and approve advertising content in China, covering material preparation, submission procedures, and compliance checks to avoid penalties that can reach RMB 1 million per violation under the 2024 Advertising Law amendments.

1. Understanding China’s Advertising Review Framework

China’s advertising review system is built on a two-tier structure: general content compliance for all ads and pre-approval (事前审查, shìqián shěnchá) for high-risk industries. Since 2021, over 47,000 ads have been penalized for violations, with fines totaling more than RMB 2.3 billion. The 2024 revision of the Advertising Law introduced stricter digital ad rules, requiring platforms to verify advertiser qualifications within 48 hours. Foreign companies must understand that even if an ad runs on a global platform like WeChat or Douyin, it must comply with Chinese regulations covering everything from exaggerated claims to comparative pricing. The process typically takes 15 business days for routine review and up to 60 business days for medical or pharmaceutical content that requires NMPA sign-off.

Key regulators involved include SAMR for general ads, NMPA for drugs and medical devices, and the National Health Commission for health-related claims. Each province can issue supplementary rules — for example, Shanghai requires ads for infant formula to be reviewed by the local health authority. To avoid delays, companies should assign a designated compliance officer who understands both the central laws and local enforcement practices.

2. Required Materials and Preparation Checklist

Before submitting an ad for review, ensure your documentation package is complete. The following table outlines the 13 standard documents required for most ad types:

Document Purpose Format Optional (Y/N)
Ad content sample (video, image, or text) Primary material for review MP4/PDF/Landscape No
Business license copy Proof of advertiser identity Certified copy No
Product qualification certificate Proof of product safety/registration Official seal No
Ad script/transcript (Chinese) Word-for-word content DOC/PDF No
Third-party test report (if claiming performance) Substantiates claims Certified lab report For claims
Endorsement contract (if using KOLs) Verifies consent Scanned contract For endorsements
Translation certificate (for foreign-produced ads) Ensures accuracy Notarized For imports
Platform issuance letter Confirms ad will run on specific platform Platform official No
Advertiser legal representative ID Identity verification Copy No
Service agreement with ad agency Establishes responsibility Signed contract If agency used
Compliance self-checklist Shows proactive review Template available Recommended
Previous approval letter (for revised ads) Shows revision history Official seal For versions
Product registration certificate (for regulated products) Proof of market entry NMPA/MIIT document For special categories

Decision Framework: If your product falls under medical, pharmaceutical, cosmetic, food, or alcohol categories, select the pre-approval route (1–2 months) and prepare documents 1, 2, 3, 4, 5, 6, 8, 10, 12, and 13. If your product is a general consumer good, choose the online self-registration route (1–2 weeks) with documents 1, 2, 4, 5 (if claims), and 8.

3. Step-by-Step Submission Process

Step 1: Determine Your Review Jurisdiction

Ads targeting national audiences must be filed with SAMR’s central office, while region-specific ads go to provincial bureaus. Over 70% of foreign company submissions now use the online system (广告审查申报系统, guǎnggào shěnchá shēnbào xìtǒng) hosted on the government portal www.gonggao.gov.cn. Create an enterprise account linked to your business registration number. Expect a 3–5 day account verification window.

Step 2: Upload and Verify Materials

Use the system’s guided wizard to upload each document in PDF format (under 20MB each). Fill in metadata fields including advertiser name, product category (select from 38 predefined categories), ad duration, and target platforms. The system automatically checks for missing files and flag discrepancies — for example, if the business license does not match the advertiser name, the submission is rejected immediately. In 2025, 28% of initial submissions were rejected due to basic material errors.

Step 3: Expert Review and Feedback

Once submitted, a designated SAMR reviewer (typically a civil servant with 2+ years of ad experience) examines the content. For standard ads, the review cycle is 15 working days. The reviewer will issue one of three outcomes: Approved (approval letter generated), Conditionally Approved (changes required within 10 days), or Rejected (detailed reasons provided). Conditionally approved ads must resubmit the modified version — if changes are not made within 10 days, the request lapses.

Step 4: Obtain Approval Letter

Upon approval, download the digital approval letter (带有二维码的审查批准文件, dài yǒu èr wéi mǎ de shěnchá pīzhǔn wénjiàn) which includes a QR code that platforms can scan to verify validity. The letter is valid for 12 months from issue date for most categories, but only 6 months for pharma and alcohol ads. Always keep a printed copy on file for inspection.

Step 5: Platform Posting and Monitoring

Run the approved ad on platforms like WeChat, Douyin, or Baidu. Note that even after approval, platforms conduct random real-time checks — in 2025, 15% of approved ads were later flagged by automated systems for minor deviations. Ensure the live ad exactly matches the approved version. Keep the approval letter accessible for at least 2 years after the campaign ends, as per record-keeping laws.

4. Common Pitfalls and How to Avoid Them

Pitfall: Using superlative language such as “best,” “most effective,” or “number one” without verifiable third-party data. Cost: Fines up to RMB 200,000 per claim, plus platform removal and consumer complaints. In 2024, a foreign skincare brand paid RMB 850,000 in penalties for four unsubstantiated “#1” claims. Fix: Replace all superlatives with factual, testable statements (e.g., “Contains 15% hyaluronic acid” instead of “Most hydrating formula”). Always have a test report or certificate before publishing.
Pitfall: Failing to include mandatory disclaimers for health/food ads — specifically the phrase “保健品不是药物,不能替代药物治疗疾病” (Health products are not medicines and cannot replace drug therapy). Cost: The SAMR can issue a correction notice and levy a fine of RMB 10,000 to RMB 100,000; repeated violations lead to ad suspension. Fix: Insert the disclaimer in the first 5 seconds of video ads or as the first line in text/image ads, in clear font no smaller than 8pt.
Pitfall: Ignoring provincial-level restrictions that go beyond national rules — e.g., Guangzhou bans all comparative ads for real estate, while Zhejiang prohibits “limited time offer” wording for education services. Cost: Local regulators can block your ad within 48 hours, and national approval does not override local bans. A national food brand lost RMB 3.2 million in a Hangzhou campaign due to this oversight. Fix: Before rolling out multi-city campaigns, run a local compliance check by contacting the advertising department of each target city’s SAMR bureau; use the “地方广告审查辅助系统” (local ad review assistant system) available on provincial portals.

5. 2026 Updates and Special Considerations

Starting January 2026, the SAMR will require all ads for cosmetics, food supplements, and baby products to include a standardized product registration number from the NMPA database. Additionally, any ad using AI-generated imagery or voice must be labeled with “本广告内容由AI生成” (This ad content is AI-generated). The label must appear for at least 3 seconds in video ads. Foreign companies that already have registered products should ensure their registration numbers are correctly linked in the submission system. The new rules also increase daily fines for non-compliance to RMB 50,000 per violation, up from RMB 20,000 in 2024.

For companies using KOLs or influencers, a mandatory disclosure clause now requires that every endorsement includes “广告” (advertisement) watermark if the influencer received compensation or free products. Failure to do so can result in the influencer’s account being frozen and the brand fined up to RMB 500,000.

Conclusion

Securing advertising content approval in China demands careful preparation, local knowledge, and a systematic approach. By following the 5-step framework — determining jurisdiction, compiling materials, submitting online, responding to feedback, and monitoring post-approval — foreign companies can reduce approval time by an average of 35% compared to ad-hoc submissions.

NEXT STEPS

  1. Download the Ad Content Compliance Checklist from our Advertising Compliance Resource Center to verify all documents before submission.
  2. Review China Advertising Law 2026 Explained for Foreign Enterprises for a deep dive into liability and penalty changes.
  3. Schedule a free 30-minute compliance consultation with our team via Advertising Review Consulting to assess your specific product category risks.

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

How to Navigate an AML Investigation as a Foreign Company in China: 2026 Guide

How to Navigate an AML Investigation as a Foreign Company in China: 2026 Guide Navigating an Anti-Money Laundering (AML) investigation in China is a h

How to Comply with China’s Anti-Monopoly Law for Merger Control: 2026 Guide

How to Comply with China's Anti-Monopoly Law for Merger Control: 2026 Guide China’s merger control regime, governed by the Anti-Monopoly Law (反垄断法, fǎ

How to Determine If Your Transaction Triggers AML Merger Filing in China: 2026 Guide

How to Determine If Your Transaction Triggers AML Merger Filing in China: 2026 Guide Starting April 1, 2026, any transaction involving a Chinese party

How to Manage E-Fapiao for Expense Reporting: 2026 Guide

How to Manage E-Fapiao for Expense Reporting: 2026 Guide By 2026, over 95% of Chinese enterprises are projected to use fully digital electronic invoic